✦ LIBER ✦

P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?

✍ Scribed by Buggisch, P.; Schober, A.; Bruch, H.R.; Antoni, C.; Loehr, H.; Herrmann, A.; Steffens, H.; Moog, G.; Haessner, J.; Hoerster, H.-G.; John, C.; Schlueter, H.-J.; Link, R.; Heyne, R.; Spengler, U.; Alshuth, U.; Hueppe, D.

Book ID: 122288798
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 117 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61296-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P1141 SUSTAINED VIROLOGICAL RESPONSE (SV

P1141 SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING

✍ Boeker, K.H.W.; Link, R.; Baumgarten, A.; Stoehr, A.; Heyne, R.; Roessle, M.; Sc 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 102 KB

P1149 PHYSICIAN ADHERENCE TO AND EFFICAC

P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING

✍ Mauss, S.; Schober, A.; John, C.; Lutz, T.; Moog, G.; Bruch, H.R.; Teuber, G.; C 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 77 KB

P1146 VIROLOGICAL RESPONSE AND TOLERANCE

P1146 VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV–HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY

✍ Baumgarten, A.; Holm, S.; Lutz, T.; Schranz, D.; Mauss, S.; Hillenbrand, H.; Mol 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB